Dakota Wealth Management Grows Stock Holdings in Tempus AI, Inc. (NASDAQ:TEM)

Dakota Wealth Management grew its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 189.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,668 shares of the company’s stock after purchasing an additional 39,724 shares during the period. Dakota Wealth Management’s holdings in Tempus AI were worth $2,048,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in TEM. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI during the 3rd quarter worth $30,000. FNY Investment Advisers LLC bought a new stake in Tempus AI in the fourth quarter worth $67,000. Vestor Capital LLC bought a new stake in Tempus AI in the third quarter worth $153,000. Stifel Financial Corp bought a new stake in Tempus AI in the third quarter worth $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Tempus AI in the third quarter worth $258,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TEM shares. Guggenheim started coverage on shares of Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Piper Sandler restated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Loop Capital cut their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Insiders Place Their Bets

In other news, major shareholder Bradley A. Keywell sold 265,000 shares of the stock in a transaction on Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the completion of the sale, the insider now directly owns 15,218,365 shares of the company’s stock, valued at $534,164,611.50. This represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the completion of the sale, the chief executive officer now directly owns 9,557,283 shares of the company’s stock, valued at approximately $358,780,403.82. This trade represents a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,300,761 shares of company stock worth $51,271,197.

Tempus AI Trading Up 8.7 %

Shares of Tempus AI stock opened at $54.84 on Friday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $79.49. The company’s 50 day moving average is $44.38 and its 200 day moving average is $47.46.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.